arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Trevi Therapeutics, Inc.

TRVI
$18.49 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
34 Visible periods
20 Metrics
Peer-ranked Benchmarks
Price Chart
37
Health
Weak
Neutral
auto_awesome

Analytical Summary

Trevi Therapeutics, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $2.7B
Dividend Yield
Revenue Growth
Op. Margin
ROIC -8.7%
FCF / Share $-0.12
Trailing P/E
Price / Book 13.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

34-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-13.19M
↓ -27.6%
FCF / Share Free cash flow per share
$-0.12
↓ -0.6%

Health Breakdown

Returns
26
Cash Quality
65

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 34 quarters